plerixafor has been researched along with HPV Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Shoshan, M; Jfri, A; Litvinov, IV; Merati, N; Popradi, G; Sivachandran, S; Vinh, DC | 1 |
| Aknin, ML; Bachelerie, F; Berrebi, D; Gaudin, F; Hémon, P; Meuris, F | 1 |
1 review(s) available for plerixafor and HPV Infection
| Article | Year |
|---|---|
Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Topics: Agammaglobulinemia; Benzylamines; Cyclams; Fantasy; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Neutropenia; Papillomavirus Infections; Primary Immunodeficiency Diseases; Receptors, CXCR4; Syndrome; Warts | 2022 |
1 other study(ies) available for plerixafor and HPV Infection
| Article | Year |
|---|---|
Symptomatic Improvement in Human Papillomavirus-Induced Epithelial Neoplasia by Specific Targeting of the CXCR4 Chemokine Receptor.
Topics: Animals; Apoptosis; Benzylamines; Cell Proliferation; Cells, Cultured; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Humans; Immunohistochemistry; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Papillomaviridae; Papillomavirus Infections; Random Allocation; Receptors, CXCR4; Skin Neoplasms | 2016 |